Published in J Exp Med on October 01, 1973
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes. J Clin Invest (1980) 12.41
Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J Exp Med (1975) 7.87
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
Effect of normal and activated human macrophages on Toxoplasma gondii. J Exp Med (1974) 4.39
Trypanosoma cruzi: in vitro induction of macrophage microbicidal activity. J Exp Med (1978) 4.29
Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria. J Exp Med (1981) 4.08
Synthesis of the second component of complement by long-term primary cultures of human monocytes. J Exp Med (1976) 3.64
Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med (1980) 3.43
Inhibition of multiplication of Toxoplasma gondii by human monocytes exposed to T-lymphocyte products. J Exp Med (1975) 3.17
Resistance and susceptibility of mice to bacterial infection: course of listeriosis in resistant or susceptible mice. Infect Immun (1978) 2.65
Inhibition of the growth of Rickettsia prowazekii in cultured fibroblasts by lymphokines. J Exp Med (1983) 2.20
Resistance and susceptibility of mice to bacterial infection: histopathology of listeriosis in resistant and susceptible strains. Infect Immun (1980) 1.97
Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo. J Exp Med (1975) 1.90
Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun (1985) 1.82
Studies on the mechanisms of macrophage activation. II. Parasite destruction in macrophages activated by supernates from concanavalin A-stimulated lymphocytes. J Exp Med (1979) 1.81
Host defenses in experimental scrub typhus: role of normal and activated macrophages. Infect Immun (1979) 1.76
Expression of systemic protection and delayed-type hypersensitivity to Listeria monocytogenes is mediated by different T-cell subsets. Infect Immun (1990) 1.69
Macrophage activation during experimental murine brucellosis: a basis for chronic infection. Infect Immun (1979) 1.54
Effect of glucocorticosteroids on the phagocytosis and intracellular killing by peritoneal macrophages. Infect Immun (1975) 1.53
Cell-mediated immunity against Besnoitia and toxoplasma in specifically and cross-immunized hamsters and in cultures. J Exp Med (1974) 1.51
Interaction between Coxiella burnetii and guinea pig peritoneal macrophages. Infect Immun (1976) 1.40
Dichotomy between macrophage activation and degree of protection against Listeria monocytogenes and Toxoplasma gondii in mice stimulated with Corynebacterium parvum. Infect Immun (1975) 1.38
Antileishmanial defense in macrophages triggered by tumor necrosis factor expressed on CD4+ T lymphocyte plasma membrane. J Exp Med (1991) 1.33
Immunocompetent cells in resistance to bacterial infections. Bacteriol Rev (1976) 1.31
Experiments on lymphocyte-mediated cellular immunity in murine histoplasmosis. Infect Immun (1977) 1.29
Cellular immunity to bacteria: impairment of in vitro lymphocyte responses to Pseudomonas aeruginosa in cystic fibrosis patients. Infect Immun (1977) 1.29
Role of transferrin, transferrin receptors, and iron in macrophage listericidal activity. J Exp Med (1991) 1.27
Mechanisms of macrophage activation. Clin Exp Immunol (1980) 1.25
Time course of antilisterial activity by immunologically activated murine peritoneal macrophages. Infect Immun (1983) 1.23
Cell-mediated immunity after bacterial infection of the lower respiratory tract. J Clin Invest (1974) 1.20
Stimulation of polymorphonuclear leukocyte bactericidal activity by supernatants of activated human mononuclear cells. Infect Immun (1978) 1.18
Fat of Coxiella burnetti in macrophages from immune guinea pigs. Infect Immun (1977) 1.16
Adoptive transfer of murine host protection to salmonellosis with T-cell growth factor-dependent, Salmonella-specific T-cell lines. Infect Immun (1985) 1.14
Appearance of cellular and humoral immunity in guinea pigs after infection with Coxiella burnetii administered in small-particle aerosols. Infect Immun (1977) 1.12
Lymphokine-induced production and release of lysosomal enzymes by macrophages. Proc Natl Acad Sci U S A (1975) 1.11
Murine encephalitozoonosis model for studying the host-parasite relationship of a chronic infection. Infect Immun (1983) 1.10
Ontogeny of macrophage-mediated protection against Listeria monocytogenes. Infect Immun (1985) 1.08
Development of cellular and humoral immunity in the respiratory tract of rabbits to Pseudomonas lipopolysaccharide. J Clin Invest (1974) 1.08
Cell-mediated immune phenomena induced by lymphokines from splenic lymphocytes of mice with chronic staphylococcal infection. Infect Immun (1975) 1.07
Listericidal activity of non-stimulated and stimulated human macrophages in vitro. Clin Exp Immunol (1977) 1.05
Cell-mediated immune responses of guinea pigs to an inactivated phase I Coxiella burnetii vaccine. Infect Immun (1978) 1.04
Radiolabelled M. leprae resident in human macrophage cultures as an in vitro indicator of effective immunity in human leprosy. Clin Exp Immunol (1982) 1.04
Alteration of some functional and metabolic characteristics of resident mouse peritoneal macrophages by lymphocyte mediators. J Exp Med (1978) 1.03
Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice. Infect Immun (1988) 0.99
Ontogeny of murine macrophages: functions related to antigen presentation. Infect Immun (1982) 0.98
Mechanism of depletion of T lymphocytes from the spleen of mice infected with Listeria monocytogenes. Infect Immun (1982) 0.97
An in vitro system to study listericidal capacity of macrophages from separate mice: resident macrophages exhibit different activation patterns. Infect Immun (1985) 0.96
In vitro quantitation of cell-mediated immunity in guinea-pigs by macrophage reduction of nitro-blue tetrazolium. Clin Exp Immunol (1976) 0.93
In vitro antilisterial activity of soluble product(s) released from Listeria-immune murine peritoneal macrophages. Infect Immun (1974) 0.90
Interactions between salmonellae and macrophages of guinea pigs. IV. Relationship between migration inhibition and antibacterial action of macrophages. Infect Immun (1977) 0.89
Enhanced hydrogen peroxide release from macrophages stimulated with streptococcal preparation OK-432. Infect Immun (1979) 0.89
Effect of delayed-type hypersensitivity reaction and transferred lymphokine on the resistance of mice to Salmonella typhimurium infection. Infect Immun (1983) 0.87
Candidacidal activity of mouse macrophages in vitro. Infect Immun (1980) 0.85
In vivo and in vitro effects of lead on humoral and cell-mediated immunity. Infect Immun (1981) 0.84
Partial purification and characterization of the human lymphocyte colony enhancing factor (LCEF). Immunology (1978) 0.83
Direct activation of human monocyte-derived macrophages by a bacterial glycoprotein extract inhibits the intracellular multiplication of virulent Legionella pneumophila serogroup 1. Infect Immun (1987) 0.83
Different effects of phytohemagglutinin-activated lymphocytes and their culture supernatants on macrophage function. Infect Immun (1976) 0.83
T-cell hybridomas reveal two distinct mechanisms of antileishmanial defense. Infect Immun (1990) 0.83
Antibacterial product of peritoneal exudate cell cultures from guinea pigs infected with mycobacteria, listeriae, and rickettsiae. Infect Immun (1977) 0.81
Macrophage function in Mycobacterium lepraemurium infection: morphological and functional changes of peritoneal and splenic macrophages in vitro. Infect Immun (1983) 0.81
Immunologically mediated macrophage aggregation in monolayers of peritoneal cells from BCG-sensitized mice. Immunology (1977) 0.80
Retracted Recombinant human migration inhibitory factor has adjuvant activity. Proc Natl Acad Sci U S A (1992) 0.79
Bronchopulmonary cellular response to aluminum and zirconium salts. Infect Immun (1978) 0.79
Interaction of subpopulations of murine lymph node lymphocytes in antigen-induced [14C]-thymidine incorporation: T and B cell synergy in the response to antigen. Immunology (1979) 0.78
Microbicidal activity and morphological characteristics of lung macrophages in Mycobacterium bovis BCG cell wall-induced lung granuloma in mice. Infect Immun (1984) 0.78
Antibacterial defence mechanisms. Infection (1983) 0.76
A journey in science: promise, purpose, privilege. Mol Med (2013) 0.75
Isolation of Acholeplasma laidlawii from commercial, serum-free tissue culture medium and studies on its survival and detection. Appl Microbiol (1974) 0.75
Cellular resistance to infection. J Exp Med (1962) 30.96
The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med (1969) 20.62
THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE. J Exp Med (1964) 13.28
Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 12.29
Requirement of thymus (T) lymphocytes for resistance to listeriosis. J Exp Med (1972) 8.25
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Demonstration in tissue culture of lymphocyte-mediated immunity to tuberculosis. Infect Immun (1970) 5.96
Cellular immunity in vitro. I. Immunologically mediated enhancement of macrophage bactericidal capacity. J Exp Med (1971) 4.94
Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med (1973) 3.98
In vitro induction of nonspecific resistance in macrophages by specifically sensitized lymphocytes. Infect Immun (1971) 3.81
Lymphocyte-mediated modification of blood-derived macrophage function in vitro; inhibition of growth of intracellular mycobacteria with lymphokines. Clin Exp Immunol (1971) 3.74
Enhancement of macrophage bactericidal capacity by antigenically stimulated immune lymphocytes. Cell Immunol (1972) 3.56
Activation of normal rabbit macrophage monolayers by supernatants of antigen-stimulated lymphocytes. J Immunol (1970) 3.17
Functional anatomy of the lymphocyte in immunological reactions in vitro. J Exp Med (1966) 2.91
Studies on migration inhibitory factor (MIF): recovery of MIF activity after purification by gel filtration and disc electrophoresis. Cell Immunol (1970) 2.86
CYTOPLASMIC INTERACTION BETWEEN MACROPHAGES AND LYMPHOCYTIC CELLS IN ANTIBODY SYNTHESIS. Science (1964) 2.77
Passive transfer of resistance to tuberculosis through use of monocytes. Proc Soc Exp Biol Med (1960) 2.22
Characterization of migration inhibitory factor (MIF) from guinea pig lymphocytes stimulated with concanavalin A. J Immunol (1972) 1.82
Activity in vitro of lymphocytes and macrophages in delayed hypersensitivity. J Immunol (1971) 1.48
Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 12.29
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Genetic variation of Drosophila melanogaster natural populations. Trends Genet (1988) 4.62
Suppression of delayed hypersensitivity in vitro by inhibition of protein synthesis. J Exp Med (1965) 4.62
A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni. J Immunol (1979) 4.17
Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med (1973) 3.98
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
An in vitro assay for cellular hypersensitivity in man. J Immunol (1970) 3.73
Cellular hypersensitivity and immunity. Inhibition of macrophage migration and the lymphocyte mediators. Prog Allergy (1972) 3.47
Macrophage migration. Fed Proc (1990) 3.39
Studies on mediator production by highly purified human T and B lymphocytes. J Exp Med (1974) 3.38
Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med (1999) 3.23
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
Studies on migration inhibitory factor (MIF): recovery of MIF activity after purification by gel filtration and disc electrophoresis. Cell Immunol (1970) 2.86
Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.84
Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.81
Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol (1979) 2.81
Cellular sensitivity to collagen in rheumatoid arthritis. N Engl J Med (1978) 2.50
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1989) 2.24
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
The compartmentalization of antigen-reactive lymphocytes in desensitized guinea pigs. J Exp Med (1971) 2.18
Metabolic and functonal studies on activated mouse macrophages. J Exp Med (1973) 2.17
Antibody-dependent eosinophil-mediated damage to 51Cr-labeled schistosomula of Schistosoma mansoni: damage by purieid eosinophils. J Exp Med (1977) 2.06
Macrophage activation by lymphocyte mediators. Fed Proc (1975) 1.99
Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg (1998) 1.99
Host-plant specialization in the Drosophila melanogaster species complex: a physiological, behavioral, and genetical analysis. Proc Natl Acad Sci U S A (1991) 1.98
Similarities and differences in latitudinal adaptation of two Drosophila sibling species. Nature (1975) 1.96
Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci U S A (1986) 1.93
Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis (2005) 1.91
Evolution in a cosmopolitan species: genetic latitudinal clines in Drosophila melanogaster wild populations. Experientia (1975) 1.91
Immunochemical studies on the specificity of cellular hypersensitivity. The in vitro inhibition of peritoneal exudate cell migration by cehmically defined antigens. J Exp Med (1968) 1.90
Monoclonal antibodies that distinguish between New World species of Leishmania. Nature (1981) 1.89
Idiopathic cardiomyopathy, age, and suppressor-cell dysfunction as risk determinants of lymphoma after cardiac transplantation. Lancet (1978) 1.87
Characterization of migration inhibitory factor (MIF) from guinea pig lymphocytes stimulated with concanavalin A. J Immunol (1972) 1.82
Mediators produced by sensitized lymphocytes. Fed Proc (1972) 1.79
Mitochondrial DNA variability in Drosophila simulans: quasi absence of polymorphism within each of the three cytoplasmic races. Heredity (Edinb) (1988) 1.76
Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol (2001) 1.74
Activation of human blood monocytes by products of sensitized lymphocytes. J Clin Invest (1974) 1.73
Defective in vitro suppressor cell function in idiopathic congestive cardiomyopathy. Circulation (1979) 1.70
Maternal-fetal relation. Absence of an immunologic blocking factor from the serum of women with chronic abortions. N Engl J Med (1976) 1.69
Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll. Exp Parasitol (1982) 1.66
Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies. Am J Trop Med Hyg (1987) 1.65
Prevention of MIF activity by agents known to increase cellular cyclic AMP. J Immunol (1973) 1.64
Transfer of cellular hypersensitivity in chronic mucocutaneous candidiasis monitored in vivo and in vitro. Cell Immunol (1970) 1.64
In vivo and in vitro characterization of murine T-cell clones reactive to Mycobacterium tuberculosis. Infect Immun (1987) 1.63
Characterization of human migration inhibitory factor (MIF) from antigen-stimulated lymphocytes. Cell Immunol (1972) 1.63
Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A (1981) 1.54
Lymphocyte mediators and cellular hypersensitivity. N Engl J Med (1973) 1.53
Schistosoma mansoni. Anti-egg monoclonal antibodies protect against cercarial challenge in vivo. J Exp Med (1984) 1.51
Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia. N Engl J Med (1980) 1.50
Genetics of morphological differences and hybrid sterility between Drosophila sechellia and its relatives. Genet Res (1991) 1.49
Enzymatic and quantitative variation in European and African populations of Drosophila simulans. Heredity (Edinb) (1985) 1.47
The Guillain-Barré syndrome and multiple sclerosis. In vitro cellular responses to nervous-tissue antigens. N Engl J Med (1971) 1.47
Biological expressions of lymphocyte activation. V. Characterization of a soluble immune response suppressor (SIRS) produced by concanavalin A-activated spleen cells. J Immunol (1976) 1.47
Autoimmunity to collagen in adjuvant arthritis of rats. J Clin Invest (1980) 1.44
Low allozyme and mtDNA variability in the island endemic species Drosophila sechellia (D. melanogaster complex). Experientia (1990) 1.42
In vitro studies of the suppression of delayed hypersensitivity by the induction of partial tolerance. J Exp Med (1970) 1.41
Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med (1987) 1.41
Stress-induced enhancement of skin immune function: A role for gamma interferon. Proc Natl Acad Sci U S A (2000) 1.39
IgE antibody and resistance to infection. I. Selective suppression of the IgE antibody response in rats diminishes the resistance and the eosinophil response to Trichinella spiralis infection. J Exp Med (1981) 1.36
Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun (2001) 1.36
In vitro lymphocyte response of patients with immunologic deficiency diseases. N Engl J Med (1970) 1.34
Interactions between human eosinophils and schistosomula of Schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence. J Exp Med (1979) 1.34
Retracted Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani. J Immunol (1991) 1.33
In vitro evidence for cellular hypersensitivity to glomerular-basement-membrane antigens in human glomerulonephritis. N Engl J Med (1970) 1.33
Retracted Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages. J Immunol (1993) 1.31
Further studies on migration inhibitory factor (MIF): evidence for its glycoprotein nature. J Immunol (1971) 1.30
Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells. J Immunol (1975) 1.27
Monoclonal antibodies that distinguish subspecies of Leishmania braziliensis. J Immunol (1982) 1.27
Biosynthetic defect in monocytes from human beings with genetic deficiency of the second component of complement. N Engl J Med (1975) 1.27
A microsatellite-based multilocus phylogeny of the Drosophila melanogaster species complex. Curr Biol (1998) 1.26
Enhancement of human blood eosinophil cytotoxicity by semi-purified eosinophil colony-stimulating factor(s). J Exp Med (1982) 1.25
Comparative analysis of morphological traits among Drosophila melanogaster and D. simulans: genetic variability, clines and phenotypic plasticity. Genetica (2004) 1.23
In vitro demonstration of cellular sensitivity in allergic encephalomyelitis. J Exp Med (1965) 1.22
Competence of the human host as a reservoir for Leishmania chagasi. J Infect Dis (2000) 1.21
Short-range genetic structure of Drosophila melanogaster populations in an Afrotropical urban area and its significance. Proc Natl Acad Sci U S A (1989) 1.21
Two dimensional echocardiographic assessment of patients with bioprosthetic valves. Am J Cardiol (1979) 1.21
Leukocyte inhibitory factor (LIF): production by purified human T and B lymphocytes. J Immunol (1975) 1.19
Biological role of alcohol dehydrogenase in the tolerance of Drosophila melanogaster to aliphatic alochols: utilization of an ADH-null mutant. Biochem Genet (1976) 1.19
Multilevel modelling of the incidence of visceral leishmaniasis in Teresina, Brazil. Epidemiol Infect (2006) 1.19
In vitro killing of S. mansoni schistosomula by lymphokine-activated mouse macrophages. J Immunol (1981) 1.18
IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol (2000) 1.17
Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis. N Engl J Med (1981) 1.17
Chill-coma tolerance, a major climatic adaptation among Drosophila species. Evolution (2001) 1.16
Effect of multiparity on human maternal hypersensitivity to foetal antigen. Nature (1973) 1.15
Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium. J Immunol (1998) 1.15
Expression of strain-specific surface antigens on Plasmodium falciparum-infected erythrocytes. Parasite Immunol (1982) 1.14
Antibody-dependent, eosinophil-mediated damage to 51Cr-labeled schistosomula of Schistosoma mansoni: effect of metabolic inhibitors and other agents which alter cell function. J Immunol (1977) 1.14
Enhanced Th2-like responses in IL-1 type 1 receptor-deficient mice. Eur J Immunol (1998) 1.13
Evolution of a lesser fitness trait: egg production in the specialist Drosophila sechellia. Genet Res (1997) 1.12
Gold does not alter the arthritic, humoral, or cellular responses in rats with type II collagen-induced arthritis. Arthritis Rheum (1980) 1.12
Bubonic leishmaniasis: a common manifestation of Leishmania (Viannia) braziliensis infection in Ceara, Brazil. Am J Trop Med Hyg (1995) 1.10
The adherence of human neutrophils and eosinophils to schistosomula: evidence for membrane fusion between cells and parasites. J Cell Biol (1980) 1.10
Sequence analysis of active mariner elements in natural populations of Drosophila simulans. Genetics (1992) 1.10
Contrasting patterns of geographic variation in the cosmopolitan sibling species Drosophila melanogaster and Drosophila simulans. Biochem Genet (1987) 1.10
STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol (1999) 1.08
Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J Immunol (1998) 1.08